Case no. | BRAFmutation | Type of targeted drug | Treatment start date | Best response (%) | TTF (months)a | Sampling date; time from treatmentb | Molecular analysis by NGS | ||
---|---|---|---|---|---|---|---|---|---|
Mutations | Amplifications/deletions | Truncations | |||||||
1 | V600E | BRAF inhibitor | 9/17/2009 | CR (−100) | 28.7+ | 5/1/2009; −4 months | BRAF (V600E) | None | None |
2 | V600E | BRAF inhibitor | 10/7/2009 | CR (−100) | 27.4+ | 1/22/2009; −9 months | BRAF (V600E); BRAF (T599S) | AURKA amplification; BRAF amplification | None |
T599S | |||||||||
3 | V600E | BRAF inhibitor | 1/27/2010 | CR (−100) | 23.6+ | 8/19/2005; −53 months | Nonec | None | None |
4 | V600E | BRAF + MEK inhibitor | 11/11/2010 | PR (−34) | 11.2 | 5/17/2011; +6 months | APC (R1171H); BRAF (V600E); NRAS (Q61R) | PTEN deletion | RB1 truncation |
5 | V600E | BRAF inhibitor | 6/17/2009 | PR (−38) | 7.9 | 12/2/2009; +6 months | BRAF (V600E) | CDKN2A deletion; CDKN2B deletion; PAX5 deletion | None |
3/23/2010; +9 months | BRAF (V600E) | CDKN2A deletion; CDKN2B deletion; PAX5 deletion | NF1 truncation | ||||||
8/24/2011; +26 months | None | None | None | ||||||
6 | V600E | MEK inhibitor | 4/1/2010 | PR (−53) | 7.0 | 9/17/2007; −31 months | BRAF (V600E) | None | None |
7 | V600E | BRAF inhibitor | 1/12/2010 | PR (−48) | 5.7 | 11/5/2009; −2 months | BRAF (V600E) | MITF amplification | None |
8 | V600E | BRAF + MEK inhibitor | 9/3/2010 | CR (−100) | 5.6 | 4/7/2009; −17 months | BRAF (V600E); NF1 (R 440*)d | None | None |
9 | V600E | BRAF inhibitor | 1/27/2010 | PR (−75) | 4.2 | 11/11/2009; −2 months | BRAF (V600E) | BRAF amplification; MET amplification; CDKN2A deletion; CDKN2B deletion | ATM truncation |
10 | V600E | BRAF inhibitor | 4/15/2010 | PR (−54) | 3.0 | 12/11/2009; −4 months | BRAF (V600E) | MYC amplification; CDKN2A deletion | None |